Diligence memo · auto-generated · as of July 2, 2026
Biopoly, Llc
Biopoly, Llc looks under-valued against its niche peers and is active on financing cadence.
Businessfiled
Biopoly, Llc operates in Biotechnology, based in FORT WAYNE.
No verified homepage on file yet — operating evidence is limited to the public record.
Capital & rounds (filed)filed
Biopoly, Llc has raised $13M in disclosed capital across 7 recorded rounds, aggregated from public filings. Its latest round is modeled as Series A (a $4.0M–$15M round).
Largest single filing: $5.0M on 2012-07-01.
Most recent recorded round closed around 2025-01-31.
Valuation (modeled)modeled
Provath models Biopoly, Llc at approximately $4.3M (range $1.2M–$8.2M). This is an algorithmic estimate from round sizes and same-niche peers — not a quoted or reported figure.
Read: Under-valued. Modeled value is 0.28× the median modeled value of Series A Biotechnology companies in 2025–2027 (157 peers) — value vs value, same stage and era.
Financing rhythm & timingmixed
Historic cadence: a new round about every 23 months.
Last raise 17 mo ago; this sector typically re-raises about every 14 months.
Raising on or ahead of the sector's normal rhythm.
The last round stepped up 3.7× from the prior — scaling.
Comparablesmixed
Capital scale ranks ahead of 61% of Biotechnology peers (4293 compared).
Modeled value ranks above 9% of those peers.
Closest niche peers: Acasti Pharma Inc., Edesa Biotech, Inc., 4DMedical Ltd, Arialys Therapeutics, Inc., Nuclein, LLC.
Peoplefiled
20 named people on file across officers, directors and signatories.
Risks & flagsmixed
No clearly named CEO/founder/principal in the surfaced records — key-person evidence is thin.